Vinva Investment Management Ltd Sells 2,200 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Vinva Investment Management Ltd cut its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 18.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,982 shares of the medical equipment provider's stock after selling 2,200 shares during the period. Vinva Investment Management Ltd's holdings in Intuitive Surgical were worth $4,783,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Hazlett Burt & Watson Inc. boosted its position in Intuitive Surgical by 5.8% during the third quarter. Hazlett Burt & Watson Inc. now owns 362 shares of the medical equipment provider's stock valued at $177,000 after acquiring an additional 20 shares during the last quarter. Mitchell Mcleod Pugh & Williams Inc. raised its holdings in shares of Intuitive Surgical by 4.1% during the third quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 503 shares of the medical equipment provider's stock valued at $247,000 after purchasing an additional 20 shares during the period. Ullmann Wealth Partners Group LLC raised its holdings in shares of Intuitive Surgical by 1.6% during the third quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider's stock valued at $653,000 after purchasing an additional 21 shares during the period. Meeder Advisory Services Inc. raised its holdings in shares of Intuitive Surgical by 0.3% during the third quarter. Meeder Advisory Services Inc. now owns 7,386 shares of the medical equipment provider's stock valued at $3,629,000 after purchasing an additional 22 shares during the period. Finally, One Wealth Management Investment & Advisory Services LLC raised its holdings in shares of Intuitive Surgical by 3.4% during the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider's stock valued at $310,000 after purchasing an additional 23 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Trading Up 0.6 %

Shares of NASDAQ ISRG traded up $3.45 during midday trading on Friday, hitting $542.00. 718,571 shares of the company's stock were exchanged, compared to its average volume of 1,452,211. Intuitive Surgical, Inc. has a 12-month low of $304.50 and a 12-month high of $552.00. The company has a market cap of $193.05 billion, a price-to-earnings ratio of 87.14, a PEG ratio of 5.30 and a beta of 1.39. The business's fifty day moving average price is $510.03 and its two-hundred day moving average price is $468.41.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, topping the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The company had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. Equities analysts expect that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ISRG. Evercore ISI reiterated a "cautious" rating on shares of Intuitive Surgical in a report on Friday, October 18th. Truist Financial upped their price objective on shares of Intuitive Surgical from $520.00 to $570.00 and gave the company a "buy" rating in a report on Monday, October 14th. Erste Group Bank raised shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Tuesday, November 19th. The Goldman Sachs Group set a $604.00 price objective on Intuitive Surgical in a report on Friday, October 18th. Finally, Wells Fargo & Company lifted their target price on Intuitive Surgical from $466.00 to $549.00 and gave the company an "overweight" rating in a research report on Friday, October 18th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $526.06.

Insider Buying and Selling

In other Intuitive Surgical news, SVP Mark Brosius sold 2,128 shares of the business's stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $515.00, for a total value of $1,095,920.00. Following the completion of the sale, the senior vice president now owns 273 shares in the company, valued at approximately $140,595. The trade was a 88.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Jamie Samath sold 108 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total value of $58,542.48. Following the completion of the sale, the chief financial officer now owns 8,757 shares of the company's stock, valued at $4,746,819.42. The trade was a 1.22 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,459 shares of company stock worth $26,080,251 in the last quarter. 0.90% of the stock is owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.